Integrating the Guardian Spatial Emanator Within AVENIR II

This study will evaluate the implementation of integrating Guardian spatial emanators into the existing AVENIR II azithromycin mass drug administration program in Niger. The objective is to assess whether Guardian can be feasibly, acceptably, and effectively delivered through the same community-based platform already used for door-to-door azithromycin distribution to children 1 to 59 months of age. Selected health center catchment areas in high-malaria-transmission settings in Niger will be randomized to integrated delivery or non-integrated delivery. The study will measure implementation outcomes including reach, coverage, acceptability, fidelity to protocol, costs, and product placement over time, and will also assess malaria-related clinic visits among children under 5 years of age using routine health facility data

NCT Number	NCT07712263
Lead Sponsor	University of California, San Francisco Collaborators: Centre de Recherche Médicale et Sanitaire, Bill and Melinda Gates Foundation, Le Programme National de Santé Oculaire, Centre de recherche et interventions en santé publique (CRISP), Ministère de la Santé Publique du Niger, S.C. Johnson & Son, Inc.
Conditions	Malaria
Enrollment	150,000 participants
Start Date	2026-12-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-22